Weekender 7/10/15

To Our New Jersey Life Sciences Community:

Welcome to another edition of the Weekender.


21st Century Cures Passes House by Wide Margin; Newx2 BioCruise Breaks Record Registration; Novartis Wins FDA Nod; Sanofi/Regeneron Drug Passes Hurdle; Celgene Announces Purchase of Merck Summit Campus; NJ Women Lead Scoring at World Cup

An Exciting Week for Drug Approvals from New Jersey:

BioNJ Member Novartis, located in Neptune City, announced that their new heart failure medicine LCZ696, now called Entresto(TM), was approved by the FDA to reduce risk of cardiovascular death and heart failure hospitalization.

Sanofi, a BioNJ Member located in Bridgewater, and Regeneron Pharmaceuticals, Inc. announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the investigational therapy Praluent® (alirocumab) Injection.
Great News for Patients Everywhere!

The House of Representatives passed the 21st Century Cures Act with a vote of 344-77, ensuring greater medical innovation and faster treatments and cures for Patients. Thank you to Congressmen Frank Pallone and Leonard Lance, whose leadership played a key role in today’s outcome, as well as all those who voted yes including: Congressmen Donald Norcross, Frank LoBiondo, Tom MacArthur, Christopher Smith, Albio Sires, Bill Pascrell Jr., Donald Payne Jr., Rodney Frelinghuysen and Congresswoman Bonnie Watson-Coleman.

Celgene and Summit — Perfect Together

BioNJ Member Celgene Corporation announced plans to acquire BioNJ Member Merck & Co., Inc.’s research and office facility located at 556 Morris Avenue in Summit, New Jersey. This expansion for Celgene, a $7.7 billion biotech company founded in 1986, supports its growth tied to a slate of advanced drugs and therapies.

Rutgers’ Carli Lloyd Considered the Women’s Soccer Play in the World

Congratulations to former Rutgers’ soccer player, Carli Lloyd, and the entire U.S. Women’s Soccer Team for their win of the World Cup Championship!

Please Ask Your Member of Congress to Oppose H.R. 9

Congress is currently considering H.R. 9, The Innovation Act. It is a bipartisan effort to produce reform in the patent system, but BioNJ believes that it does not provide the protection that legitimate patent holders need. Please contact your Member of Congress and ask that he/she vote “NO” on H.R. 9 unless additional, meaningful IPR reforms are included.  

A Poll from BioSpace

As New Jersey biotech booms, will it take overtake other states as prime location? Click here to take a poll. 

Record Crowds Expected for the BioCruise

Next week BioNJ and NewYorkBIO will host the Newx2 BioCruise, a networking event celebrating the NJ/NY biotechnology community. Taking place Wednesday, July 15 on the New York Harbor, BioCruise has already broken all registration records!

Click here for this week’s Weekender.